Effect of Postoperative Radiotherapy on Survival in Patients with Completely Resected and Pathologically Confirmed Stage N2 Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2023 Sep 18

PMID 37720592

Authors

Lin Wang

Wenyu Chen

Xiaofei Xu

Wenbo Chen

Derong Bao

Ye Zhang

Yufen Xu

Affiliations

Soon will be listed here.

Abstract

Background: The role of postoperative radiotherapy (PORT) for patients with completely resected stage N2 non-small-cell lung cancer (NSCLC) has been controversial. This study aimed to investigate the efficacy of PORT and prognosis in these patients.

Objectives: An updated meta-analysis was conducted in this study to investigate the efficacy of PORT and prognosis in patients with completely resected and pathologically confirmed stage N2 NSCLC.

Design: This study is a systematic review and meta-analysis.

Data Source And Methods: Databases were searched up to 2 March 2022. All trials on patients with completely resected and pathologically confirmed stage N2 NSCLC undergoing PORT were screened, and data indicators in the PORT and non-PORT groups were extracted, respectively. The effect of PORT on overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) was estimated. Subgroup and sensitivity analyses were performed.

Results: In all, 20 studies involving 6340 patients were finally included. The PORT significantly increased OS [hazard ratio (HR) = 0.77, 95% CI: 0.71-0.84, < 0.001), LRFS (HR = 0.63, 95% CI: 0.52-0.76, < 0.001), and DFS (HR = 0.72, 95% CI: 0.63-0.82, < 0.001) while it showed no significant difference in improving DMFS (HR = 0.86, 95% CI: 0.71-1.05, = 0.14).

Conclusion: Our results suggest that in the postoperative treatment of patients with completely resected and pathologically confirmed stage N2 NSCLC, the addition of PORT provides better local recurrence control and survival benefit, but no benefit for distant metastases. The PORT may be incorporated into the postoperative treatment options for some patients with high-risk factors. However, it needs to be validated by more prospective studies in the future.

Trail Registration: CRD42022314095.

Citing Articles

A survival nomogram model for patients with resectable non-small cell lung cancer and lymph node metastasis (N1 or N2) based on the Surveillance, Epidemiology, and End Results Database and single-center data.

He C, Ni M, Liu J, Teng X, Ke L, Matsuura Y Transl Lung Cancer Res. 2024; 13(3):573-586.

PMID: 38601448 PMC: 11002513. DOI: 10.21037/tlcr-24-119.

Network-based identification of key proteins and repositioning of drugs for non-small cell lung cancer.

Adeyemo O, Ashimiyu-Abdusalam Z, Adewunmi M, Ayano T, Sohaib M, Abdel-Salam R Cancer Rep (Hoboken). 2024; 7(4):e2031.

PMID: 38600056 PMC: 11006715. DOI: 10.1002/cnr2.2031.

References

Suveg K, Le Pechoux C, Faivre-Finn C, Putora P, De Ruysscher D, Widder J . Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART. Clin Lung Cancer. 2021; 22(6):579-586. DOI: 10.1016/j.cllc.2021.08.007. View

DeCamp Jr M, Ashiku S, Thurer R . The role of surgery in N2 non-small cell lung cancer. Clin Cancer Res. 2005; 11(13 Pt 2):5033s-5037s. DOI: 10.1158/1078-0432.CCR-05-9013. View

Robinson C, Patel A, Bradley J, DeWees T, Waqar S, Morgensztern D . Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol. 2015; 33(8):870-6. PMC: 4348635. DOI: 10.1200/JCO.2014.58.5380. View

Belani C, Choy H, Bonomi P, Scott C, Travis P, Haluschak J . Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005; 23(25):5883-91. DOI: 10.1200/JCO.2005.55.405. View

Zhang H, Zhang D, Ju T, Zhou J . The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: a systematic review and meta-analysis. Neoplasma. 2019; 66(5):717-726. DOI: 10.4149/neo_2018_181213N965. View

Herskovic A, Mauer E, Christos P, Nagar H . Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database. J Thorac Oncol. 2016; 12(2):302-313. DOI: 10.1016/j.jtho.2016.09.135. View

Scotti V, Meattini I, Saieva C, Agresti B, De Luca Cardillo C, Bastiani P . Post-operative radiotherapy in N2 non-small cell lung cancer: a retrospective analysis of 175 patients. Radiother Oncol. 2010; 96(1):84-8. DOI: 10.1016/j.radonc.2010.05.010. View

Deng W, Xu T, Xu Y, Wang Y, Liu X, Zhao Y . Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach. J Thorac Oncol. 2018; 13(12):1968-1974. PMC: 6552655. DOI: 10.1016/j.jtho.2018.08.2021. View

Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba J . Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7(9):719-27. DOI: 10.1016/S1470-2045(06)70804-X. View

10.

Sakib N, Li N, Zhu X, Li D, Li Y, Wang H . Effect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysis. Nucl Med Commun. 2017; 39(1):51-59. DOI: 10.1097/MNM.0000000000000764. View

11.

Spoelstra F, Senan S, Le Pechoux C, Ishikura S, Casas F, Ball D . Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys. 2009; 76(4):1106-13. DOI: 10.1016/j.ijrobp.2009.02.072. View

12.

Yuan C, Tao X, Zheng D, Pan Y, Ye T, Hu H . The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer. J Surg Oncol. 2018; 119(3):379-387. DOI: 10.1002/jso.25308. View

13.

Vogelius I, Bentzen S . A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012; 51(8):975-83. PMC: 3557496. DOI: 10.3109/0284186X.2012.718093. View

14.

Zhang B, Zhao L, Yuan Z, Pang Q, Wang P . The influence of the metastasis pattern of mediastinal lymph nodes on the postoperative radiotherapy's efficacy for the IIIA-pN2 non-small-cell lung cancer: a retrospective analysis of 220 patients. Onco Targets Ther. 2016; 9:6161-6169. PMC: 5067020. DOI: 10.2147/OTT.S103565. View

15.

Lee H, Kim Y, Oh S, Lee Y, Lee D, Song J . The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer. Radiat Oncol J. 2014; 32(3):147-55. PMC: 4194297. DOI: 10.3857/roj.2014.32.3.147. View

16.

Yang H, Wang K, Li S, Li Y, Yuan L . The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy. Pathol Oncol Res. 2021; 27:1609898. PMC: 8382988. DOI: 10.3389/pore.2021.1609898. View

17.

Stephens R, Girling D, Bleehen N, Moghissi K, Yosef H, Machin D . The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996; 74(4):632-9. PMC: 2074683. DOI: 10.1038/bjc.1996.413. View

18.

Xu Y, Li J, Wang J, Hu X, Ma H, Li P . Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer. Oncol Lett. 2018; 15(2):2641-2650. PMC: 5777368. DOI: 10.3892/ol.2017.7601. View

19.

Zhang B, Yuan Z, Zhao L, Pang Q, Wang P . Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients. Oncotarget. 2017; 8(23):37208-37216. PMC: 5514903. DOI: 10.18632/oncotarget.16564. View

20.

Sun J, Noh J, Oh D, Kim H, Lee S, Choi Y . Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(12):1806-1813. DOI: 10.1016/j.jtho.2017.09.1954. View